-
New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight
13 Dec 2025 03:05 GMT
… trial also assessed how much retatrutide reduced pain from knee osteoarthritis … drugs] until you do studies comparing the medications … S. Food and Drug Administration (FDA) hasn’t approved … appetite reduction, and development of disordered eating,” Dushay …
-
STAT+: Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations
11 Dec 2025 21:46 GMT
… far in a late-stage trial, but rates of side … and many participants discontinued the treatment, including people who felt they … osteoarthritis, those who took the highest dose and stayed on the drug … the trial and that some people stopped using the drug “for …
-
New Meta-analysis Finds No Superiority of BMAC Over PRP for Knee Osteoarthritis
12 Dec 2025 18:39 GMT
… Plasma (PRP) for knee osteoarthritis (KOA). The findings … disease.
The study synthesized data from two randomized controlled trials … reduction between the two treatments across follow-up … therapies, and clinical guideline development.
About Daradia: The …
-
Hyperglycemia Worsens Osteoarthritis by Altering Macrophages
12 Dec 2025 17:47 GMT
… joint disease, which affects millions worldwide.
Osteoarthritis is … expedite the development of novel disease-modifying osteoarthritis drugs (DMOADs) … and osteoarthritisinflammation in osteoarthritis progressionmacrophage efferocytosis dysfunctionmetabolic …
-
Study uncovers beneficial relationship between gardening and osteoarthritis
12 Dec 2025 17:23 GMT
… have X-ray evidence of disease, knee pain or both. … 60s. The way that osteoarthritis develops and evolves makes it … symptoms develop is difficult to do in a clinical trial.
“ … anti-depressive medications are helpful in reducing pain in osteoarthritis, this …
-
Eli Lilly touts strong results of new experimental weight loss drug retatrutide
12 Dec 2025 16:54 GMT
… or exceed — existing blockbuster treatments.
What the study found
According … The trial enrolled patients with obesity and knee osteoarthritis who … Eli Lilly’s current drug Zepbound produced an … diarrhea compared to existing drugs. Some patients also dropped …
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
12 Dec 2025 14:19 GMT
… after 68 weeks of treatment.
Discover B2B Marketing That … drug in adult patients with obesity or overweight and knee osteoarthritis … the US Food and Drug Administration (FDA) on the approval … leading industry insights.
Clinical Trials Arena Excellence Awards - …
-
Osteoarthritis Programme Launched At Midlands Hospital
12 Dec 2025 12:12 GMT
… and knee osteoarthritis (OA).
It was developed in Denmark … scores decreased by 23%.
Medication Use: 45% of participants … or significantly less pain medication.
Improved Function: Sit-to … care for patients with osteoarthritis,” said Ciara Galvin, …
-
Lilly’s next-gen drug shows greater weight loss than Zepbound in late-stage trial
12 Dec 2025 04:00 GMT
… with obesity and osteoarthritis of the knee.
TRIAL DEPARTURES ATTRIBUTED TO … typically seen in weight-loss treatment trials, the company said, … Triple-G weight loss drugs are expected to produce … is also developing a “triple-G” weight-loss drug candidate …
-
Lilly’s triple agonist delivers up to 71.2 lbs of weight loss in Phase 3 trial
11 Dec 2025 22:47 GMT
… in patients with knee osteoarthritis, with Western Ontario and … McMaster Universities Osteoarthritis Index (WOMAC) pain scores … patient selection.
Filed Under: clinical trials, Drug Discovery, Endocrinology, Gastroenterology, Uncategorized …